Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma

Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma

Immune checkpoint inhibitor (ICI) therapy has been a paradigm shift in the treatment of cancer. ICI therapy results in durable responses and survival benefit for a large number of tumor types. Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has...

Full description

Bibliographic Details
Main Authors: Yue A. Qi, Tapan K. Maity, Shaojian Gao, Tao Gong, Meriam Bahta, Abhilash Venugopalan, Xu Zhang, Udayan Guha
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cancers
Subjects:
HLA
immunopeptidome
antigen presentation
SILAC
proteomics
immune evasion
Online Access:https://www.mdpi.com/2072-6694/13/19/4977

Internet

https://www.mdpi.com/2072-6694/13/19/4977

Similar Items